Nuvectis Pharma has transformed from a single-drug oncology company into a rare-disease player by licensing worldwide rights (outside China) to NXP100, an oral therapy for paroxysmal nocturnal hemoglobinuria (PNH), and NXP200, an oncology asset, from Haisco Pharmaceutical Group. NXP100 showed strong Phase 3 results, outperforming the standard infused drug eculizumab with a 59.5% transfusion-free normal hemoglobin response versus 8.3%. Regulatory approval decisions in China are expected within 6 to 12 months, targeting late 2026 or early 2027. This move positions Nuvectis in a fast-growing market, with the global PNH treatment market projected to nearly double by 2030, and adds multiple near-term catalysts including upcoming oncology data and regulatory reviews.
Investor Michael Burry has taken a short position on the iShares Semiconductor ETF, betting against the fund despite its strong performance, which has seen a 73% gain so far in 2026. This move highlights Burry's skepticism about the semiconductor sec...
Oklo, a nuclear energy company, has received authorization to start up its Groves Reactor. This approval marks a significant regulatory milestone for Oklo, allowing it to move forward with its plans to develop advanced nuclear technology. The startup...
Houthi rebels attacked two Saudi oil tankers in the Red Sea, the first such strikes since 2019, causing Brent crude oil prices to surge over 7% and surpass $100 per barrel. This escalation follows the collapse of a truce between the Houthis and Saudi...
Between 2023 and 2025, Ripple invested about $4 billion acquiring six companies to assemble a full institutional finance platform including custody, prime brokerage, corporate treasury, and payment infrastructure. These acquisitions form a bank-like ...
Several US asset managers, including Ledger Capital and Realta Investment Advisors, are adding XRP-linked ETFs to their portfolios, reflecting growing institutional adoption of Ripple-related investments. These ETFs offer a regulated, familiar way fo...
